Related Experiment Video

Updated: Jan 22, 2026

Promoter Capture Hi-C: High-resolution, Genome-wide Profiling of Promoter Interactions
10:16

Promoter Capture Hi-C: High-resolution, Genome-wide Profiling of Promoter Interactions

Published on: June 28, 2018

33.4K

Long noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2

W Wang1, M-L Dong, W Zhang

  • 1Department of Pharmacy, Yantai Yuhuangding Hospital, Yantai, China. liutao567@163.com.

European Review for Medical and Pharmacological Sciences
|July 13, 2019
PubMed
Abstract

Insights

Long noncoding RNA LUCAT1 promotes cisplatin resistance in non-small cell lung cancer (NSCLC) by affecting cell cycle and apoptosis. Targeting LUCAT1 may offer a new therapeutic strategy for NSCLC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Drug resistance is a significant challenge in treating non-small cell lung cancer (NSCLC).
  • Long noncoding RNAs (lncRNAs) have emerged as key regulators in NSCLC drug resistance.
  • LncRNA LUCAT1's role in cisplatin resistance warrants further investigation.

Purpose of the Study:

  • To investigate the function of lncRNA LUCAT1 in cisplatin resistance in NSCLC.
  • To explore the underlying molecular mechanism of LUCAT1 in NSCLC cisplatin resistance.

Main Methods:

  • Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) to measure LUCAT1 expression.
  • Cell Counting Kit-8 (CCK-8) assay and flow cytometry to assess cell viability and apoptosis.
  • Mechanism assays to elucidate the regulatory pathways involved.

Main Results:

  • LUCAT1 expression was significantly higher in cisplatin-resistant NSCLC cells (A549/DDP) compared to sensitive cells (A549).
  • Overexpression of LUCAT1 enhanced cisplatin resistance, inhibited cell apoptosis, and altered cell cycle distribution in NSCLC cells.
  • LUCAT1 overexpression led to increased Insulin-like Growth Factor 2 (IGF-2) expression.

Conclusions:

  • LUCAT1 promotes cisplatin resistance in NSCLC by regulating cell cycle and apoptosis.
  • LUCAT1 targets IGF-2, contributing to its role in chemoresistance.
  • LUCAT1 represents a potential therapeutic target for overcoming cisplatin resistance in NSCLC.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K
Plant Promoter Analysis: Identification and Characterization of Root Nodule Specific Promoter in the Common Bean10:58

Plant Promoter Analysis: Identification and Characterization of Root Nodule Specific Promoter in the Common Bean

Published on: December 23, 2017

13.0K

Related Concept Videos

The Eukaryotic Promoter Region02:40

The Eukaryotic Promoter Region

The eukaryotic promoter region is a segment of DNA located upstream of a gene. It contains an RNA polymerase binding site, a transcription start site, and several cis-regulatory sequences.  The proximal promoter region is located in the vicinity of the gene and has cis-regulatory sequences and the core promoter. The core promoter is the binding site for RNA polymerase and is usually located between -35 and +35 nucleotides from the transcription start site. The distal promoter regions are...
18.7K
The Eukaryotic Promoter Region02:40

The Eukaryotic Promoter Region

3.8K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.3K
Models of Health Promotion and Illness Prevention II01:18

Models of Health Promotion and Illness Prevention II

The person's health status fluctuates continually, varying from being in good health to becoming ill and returning to being healthy. To understand the concept of illness prevention, there are two models. First, the health-illness continuum model is a graphic representation of an individual's wellness. It states that a person is considered healthy in the absence of physical disease and the presence of good emotional health.
The agent-host-environment model states that disease results...
2.0K
Levels of Health Promotion and Illness Prevention01:26

Levels of Health Promotion and Illness Prevention

Health promotion allows a person to control the determinants of health, resulting in an improved health status. It enhances the quality of life and reduces premature deaths. Health promotion and illness prevention programs help people make beneficial choices to reduce the risk of disease and disabilities. There are three health promotion and illness prevention levels: primary, secondary, and tertiary prevention.
In primary prevention, actions taken before disease onset prevent the disease from...
14.4K
Models of Health Promotion and Illness Prevention I01:25

Models of Health Promotion and Illness Prevention I

A model is a theoretical way to understand a concept or an idea. Models can overcome barriers to health regardless of diverse economic and cultural backgrounds. In addition, models make the task easier by providing different ways to approach complex issues. There are two major health promotion models: the health belief model and the health promotion model.
The health belief model (HBM) attempts to predict health-related behavior in specific belief patterns. According to the HBM, a person's...
2.7K